Caffeine is a central nervous system stimulant. It works by stimulating the brain. Caffeine is found naturally in foods and beverages such as coffee, tea, colas, energy and chocolate. Botanical sources of Caffeine include kola nuts, guarana, and yerba mate. Caffeine is also available in prescription and non-prescription medications.
Caffeine is used to restore mental alertness or wakefulness during fatigue or drowsiness. Caffeine is also found in some headache and migraine medications, in certain dietary supplements used for weight loss, and in many popular energy drinks.
Caffeine citrate (Caffeine) is available by prescription only. It is used for short-term treatment of neonatal apnea (breathing problems).
Caffeine may also be used for other conditions as determined by your health care provider.
Caffeine indications
An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored
Caffeine and Sodium Benzoate Injection has been used in conjunction with supportive measure to treat respiratory depression associated with overdosage with CNS depressant drugs (e.g., narcotic analgesics, alcohol). However, because of questionable benefit and transient action, most authorities believe Caffeine and other analeptics should not be used in these conditions and recommend other supportive therapy.
How should I use Caffeine?
Use Caffeine as directed by your health care provider. If the medication is OTC, check the label on the bottle for the exact dosing instructions. If you have any questions about the use of an OTC medication, ask your pharmacist.
Caffeine may be taken with or without food. If Caffeine upsets your stomach, take it with food.
Do not exceed the recommended dose of Caffeine. Caffeine can be habit-forming.
Most OTC medications used for mental alertness contain 200 milligrams of Caffeine per tablet or capsule. The usual maximum recommended dose of OTC Caffeine is no more than 200 mg every 3-4 hours, or 1600 mg per day.
Do not double-up on your Caffeine dose if you should miss the time for next dose.
The average cup of coffee contains 150-200 milligrams (mg) of Caffeine per cup, while a cup of tea will have about 60 mg of Caffeine. Cola products have about 30-40 mg of Caffeine, and most energy drinks have about 60-70 mg. Be sure to account for any dietary Caffeine that is consumed.
Ask your health care provider any questions you may have about how to use Caffeine.
Uses of Caffeine in details
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored
This medication is used occasionally to help you stay awake and alert when you are feeling tired and/or drowsy. Caffeine is a mild stimulant.
This medication should not be used to replace sleep.
This medication should not be used in children younger than 12 years old.
How to use Caffeine
Take this product by mouth as directed. Follow all directions on the product package, or take as directed by your doctor. If you are uncertain about any of the information, consult your doctor or pharmacist.
This medication should only be used as needed, not on a regular basis. Though very unlikely, this medication may be habit-forming. Do not increase your dose, take it more frequently than directed, or take it regularly for a long time.
This medication may cause withdrawal reactions, especially if it has been used regularly for a long time or in high doses. In such cases, withdrawal symptoms (such as headaches, mental/mood changes such as irritation/nervousness) may occur if you suddenly stop using this medication. To prevent withdrawal reactions, your doctor may reduce your dose gradually. Consult your doctor or pharmacist for more details, and report any withdrawal reactions right away.
When used for an extended period, this medication may not work as well. Talk with your doctor if this medication stops working well.
Tell your doctor if your condition persists, worsens, or continues to occur again. If you think you may have a serious medical problem, seek immediate medical attention.
Caffeine description
sponsored
A methylxanthine naturally occurring in some beverages and also used as a pharmacological agent. Caffeine's most notable pharmacological effect is as a central nervous system stimulant, increasing alertness and producing agitation. It also relaxes smooth muscle, stimulates cardiac muscle, stimulates diuresis, and appears to be useful in the treatment of some types of headache. Several cellular actions of Caffeine have been observed, but it is not entirely clear how each contributes to its pharmacological profile. Among the most important are inhibition of cyclic nucleotide phosphodiesterases, antagonism of adenosine receptors, and modulation of intracellular calcium handling. [PubChem]
Caffeine dosage
Usual Adult Dose for Drowsiness:
100 to 200 mg orally not more often than every 3 to 4 hours.
For occasional use only.
Not intended for use as a substitute for sleep.
Limit the use of Caffeine containing medications, foods, or beverages while taking this product because too much Caffeine may cause nervousness, irritability, sleeplessness, and occasionally, rapid heartbeat.
Usual Pediatric Dose for Drowsiness:
>= 12 years: 100 to 200 mg not more often than every 3 to 4 hours.
For occasional use only.
Not intended for use as a substitute for sleep.
Limit the use of Caffeine containing medications, foods, or beverages while taking this product because too much Caffeine may cause nervousness, irritability, sleeplessness, and occasionally, rapid heartbeat.
Usual Pediatric Dose for Apnea of Prematurity:
For short term treatment of apnea of prematurity in infants between 28 and <33 weeks gestational age.
Prior to initiation of Caffeine citrate, baseline serum levels of Caffeine should be measured in infants previously treated with theophylline, since preterm infants metabolize theophylline to Caffeine. Likewise, baseline serum levels of Caffeine should be measured in infants born to mothers who consumed Caffeine prior to delivery, since Caffeine readily crosses the placenta.
Maintenance Dose: 5 mg/kg Caffeine citrate intravenous (over 10 minutes) or orally every 24 hours.
Note: The dose of Caffeine base is one-half the dose when expressed as Caffeine citrate (e.g., 20 mg of Caffeine citrate is equivalent to 10 mg of Caffeine base).
Serum concentrations of Caffeine may need to be monitored periodically throughout treatment to avoid toxicity. Serious toxicity has been associated with serum levels greater than 50 mg/L.
Apnea of prematurity is a diagnosis of exclusion. Other causes of apnea (e.g., central nervous system disorders, primary lung disease, anemia, sepsis, metabolic disturbances, cardiovascular abnormalities, or obstructive apnea) should be ruled out or properly treated prior to initiation of Caffeine citrate.
Caffeine citrate should be used with caution in infants with seizure disorders or cardiovascular disease.
The duration of treatment of apnea of prematurity in the placebo-controlled trial was limited to 10 to 12 days. The safety and efficacy of Caffeine citrate for longer periods of treatment have not been established.
Acebrophylline: May enhance the stimulatory effect of CNS Stimulants. Avoid combination
Adenosine: Caffeine and Caffeine Containing Products may diminish the therapeutic effect of Adenosine. Management: Monitor for decreased effect of adenosine if patient is receiving Caffeine. Discontinue Caffeine in advance of scheduled diagnostic use of adenosine whenever possible. Consider therapy modification
Amifampridine: Agents With Seizure Threshold Lowering Potential may enhance the neuroexcitatory and/or seizure-potentiating effect of Amifampridine. Monitor therapy
AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics. Monitor therapy
Broccoli: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). Monitor therapy
Bromperidol: Caffeine and Caffeine Containing Products may decrease the absorption of Bromperidol. Monitor therapy
BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential. Monitor therapy
Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics. Exceptions: Cannabidiol. Monitor therapy
Cannabis: May decrease the serum concentration of CYP1A2 Substrates (High risk with Inducers). Monitor therapy
CloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs. Monitor therapy
Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Consider therapy modification
CYP1A2 Inducers (Moderate): May decrease the serum concentration of Caffeine and Caffeine Containing Products. Monitor therapy
CYP1A2 Inhibitors (Moderate): May increase the serum concentration of Caffeine and Caffeine Containing Products. Monitor therapy
CYP1A2 Inhibitors (Strong): May increase the serum concentration of Caffeine and Caffeine Containing Products. Monitor therapy
Doxofylline: Caffeine and Caffeine Containing Products may enhance the adverse/toxic effect of Doxofylline. Avoid combination
Esketamine: May enhance the hypertensive effect of CNS Stimulants. Monitor therapy
Formoterol: Caffeine and Caffeine Containing Products may enhance the adverse/toxic effect of Formoterol. Caffeine and Caffeine Containing Products may enhance the hypokalemic effect of Formoterol. Monitor therapy
Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics. Monitor therapy
Indacaterol: Caffeine and Caffeine Containing Products may enhance the adverse/toxic effect of Indacaterol. Caffeine and Caffeine Containing Products may enhance the hypokalemic effect of Indacaterol. Monitor therapy
Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants. Consider therapy modification
Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants. Consider therapy modification
Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased. Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants. Consider therapy modification
Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available. Consider therapy modification
Lithium: Caffeine and Caffeine Containing Products may decrease the serum concentration of Lithium. Monitor therapy
Norfloxacin: May increase the serum concentration of Caffeine and Caffeine Containing Products. Monitor therapy
Olodaterol: Caffeine and Caffeine Containing Products may enhance the adverse/toxic effect of Olodaterol. Caffeine and Caffeine Containing Products may enhance the hypokalemic effect of Olodaterol. Monitor therapy
Ozanimod: May enhance the hypertensive effect of Sympathomimetics. Management: Concomitant use of ozanimod with sympathomimetic agents is not recommended. If combined, monitor patients closely for the development of hypertension, including hypertensive crises. Consider therapy modification
Pipemidic Acid: May increase the serum concentration of Caffeine and Caffeine Containing Products. Monitor therapy
Regadenoson: Caffeine and Caffeine Containing Products may diminish the vasodilatory effect of Regadenoson. Management: Avoiding using Caffeine or other methylxanthine containing products (e.g., theophylline) for at least 12 hours prior to the administration of regadenoson. Consider therapy modification
Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. Monitor therapy
Solriamfetol: CNS Stimulants may enhance the hypertensive effect of Solriamfetol. CNS Stimulants may enhance the tachycardic effect of Solriamfetol. Monitor therapy
Stiripentol: May increase the serum concentration of Caffeine and Caffeine Containing Products. Avoid combination
Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Monitor therapy
Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Monitor therapy
Theophylline Derivatives: CYP1A2 Inhibitors (Weak) may increase the serum concentration of Theophylline Derivatives. Exceptions: Dyphylline. Monitor therapy
TiZANidine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of TiZANidine. Management: Avoid these combinations when possible. If combined use is necessary, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased effects of tizanidine, including adverse reactions. Consider therapy modification
Tobacco (Smoked): May decrease the serum concentration of Caffeine and Caffeine Containing Products. Monitor therapy
Overall, the reported number of adverse events in the double-blind period of the controlled trial was similar for the Caffeine Citrate and placebo groups. The following table shows adverse events that occurred in the double-blind period of the controlled trial and that were more frequent in Caffeine Citrate-treated patients than placebo.
ADVERSE EVENTS THAT OCCURRED MORE FREQUENTLY IN Caffeine Citrate-TREATED PATIENTS THAN PLACEBO DURING DOUBLE-BLIND THERAPY
Adverse Event (AE)
Caffeine Citrate
N=46
n (%)
Placebo
N=39
n (%)
BODY AS A WHOLE
Accidental Injury
1 (2.2)
0 (0)
Feeding Intolerance
4 (8.7)
2 (5.1)
Sepsis
2 (4.3)
0 (0)
CARDIOVASCULAR SYSTEM
Hemorrhage
1 (2.2)
0 (0)
DIGESTIVE SYSTEM
Necrotizing Enterocolitis
2 (4.3)
1 (2.6)
Gastritis
1 (2.2)
0 (0)
Gastrointestinal Hemorrhage
1 (2.2)
0 (0)
HEMIC AND LYMPHATIC SYSTEM
Disseminated Intravascular Coagulation
1 (2.2)
0 (0)
METABOLIC AND NUTRITIVE DISORDERS
Acidosis
1 (2.2)
0 (0)
Healing Abnormal
1 (2.2)
0 (0)
NERVOUS SYSTEM
Cerebral Hemorrhage
1 (2.2)
0 (0)
RESPIRATORY SYSTEM
Dyspnea
1 (2.2)
0 (0)
Lung Edema
1 (2.2)
0 (0)
SKIN AND APPENDAGES
Dry Skin
1 (2.2)
0 (0)
Rash
4 (8.7)
3 (7.7)
Skin Breakdown
1 (2.2)
0 (0)
SPECIAL SENSES
Retinopathy of Prematurity
1 (2.2)
0 (0)
UROGENITAL SYSTEM
Kidney Failure
1 (2.2)
0 (0)
In addition to the cases above, three cases of necrotizing enterocolitis were diagnosed in patients receiving Caffeine Citrate during the open-label phase of the study.
Three of the infants who developed necrotizing enterocolitis during the trial died. All had been exposed to Caffeine. Two were randomized to Caffeine, and one placebo patient was “rescued” with open-label Caffeine for uncontrolled apnea.
Adverse events described in the published literature include: central nervous system stimulation (i.e., irritability, restlessness, jitteriness), cardiovascular effects (i.e., tachycardia, increased left ventricular output, and increased stroke volume), gastrointestinal effects (i.e., increased gastric aspirate, gastrointestinal intolerance), alterations in serum glucose (i.e., hypoglycemia and hyperglycemia), and renal effects (i.e., increased urine flow rate, increased creatinine clearance, and increased sodium and calcium excretion). Published long-term follow-up studies have not shown Caffeine to adversely affect neurological development or growth parameters.
Caffeine citrate should not be given to a child who has had an allergic reaction to it in the past.
Before using Caffeine citrate, tell the doctor if your child is allergic to any drugs, or has a seizure disorder, heart disease, kidney disease, liver disease, or high or low blood sugar.
Do not use the medication for longer than 12 days without the advice of your child's doctor.
Each bottle of Caffeine citrate is for one use only, even if your child does not use the entire bottle for a single dose. Throw away any medication left over in the bottle after measuring your child's dose.
Call your doctor if the child's breathing symptoms do not improve after using Caffeine citrate.
To be sure Caffeine citrate is helping your child's condition, the child's blood will need to be tested on a regular basis. Do not miss any scheduled appointments.
Active ingredient matches for Caffeine:
Caffeine
Unit description / dosage (Manufacturer)
Price, USD
Tablet; Oral; Caffeine 200 mg
Liquid; Oral; Caffeine 200 mg / 500 ml
Capsule; Oral; Caffeine 200 mg
Injectable; Injection; Caffeine Citrate 10 mg / ml
DailyMed. "CAFFEINE; ERGOTAMINE TARTRATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
The results of a survey conducted on ndrugs.com for Caffeine are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Caffeine. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
User reports
Consumer reported useful
No survey data has been collected yet
1 consumer reported price estimates
Was the price you paid to purchase the drug reasonable? Did you feel it was expensive? The below mentioned numbers have been reported by ndrugs.com website users about whether the Caffeine drug is expensive or inexpensive. There is a mixed opinion among users. The rating about the cost of the drug depends on factors like which brand drug the patient purchased, how effective it was for the price paid, the country or place the drug is marketed, and the economic condition of the patient. The users who feel the drug is expensive can look for an alternative brand drug or a generic drug to save the cost.
Users
%
Expensive
1
100.0%
Consumer reported time for results
No survey data has been collected yet
1 consumer reported age
Users
%
30-45
1
100.0%
Consumer reviews
There are no reviews yet. Be the first to write one!